Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lymphoma, B-Cell 5Lymphoma 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Hematologic Neoplasms 2Neurotoxicity Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1HIV Infections 1Disease Progression 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × axicabtagene ciloleucel × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
22 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡